BMS-986318

oral FXR agonist for NASH

robust in vivo PD, phase I HV study withdrawn

from prior FXR agonists

ACS Med. Chem. Lett

Bristol Myers Squibb, Princeton, NJ, USA

The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I study. The molecule exhibits potent in vitro and in…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.